Serum GFAP differentiated Alzheimer’s disease patients from control with an area under the curve (AUC) of 0.87 and from behavioural frontotemporal dementia with an AUC of 0.81, highlighting GFAP’s potential as a differential biomarker. The gene discussed is GFAP; the disease is Alzheimer disease.